YD Bio (YDES) Cash & Equivalents (2024 - 2025)
YD Bio's (YDES) quarterly Cash & Equivalents came in at $6.0 million in Q4 2025, up 91.8% year-on-year from $3.1 million in Q4 2024, and up 1179.52% on a QoQ basis from $469520.0 in Q2 2025.
YD Bio (YDES) Cash & Equivalents (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Cash & Equivalents data on file, last reported at $6.0 million in Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 91.8% year-over-year to $6.0 million in Q4 2025; TTM through Dec 2025 was $6.0 million, a 91.8% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 91.8% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $6.0 million, up from $469520.0 in the prior quarter.
- Over the last five years, Cash & Equivalents for YDES reached as high as $6.0 million in Q4 2025 and fell as low as $469520.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 440.94 Mn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 6.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.01 Mn |
| Jun 30, 2025 | 469,520.00 |
| Dec 31, 2024 | 3.13 Mn |